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Abstract 
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The evidence base available to trialists to support trial process decisions– e.g. how best to 
recruit and retain participants, how to collect data or how to share the results with 
participants – is thin.  One way to fill gaps in evidence is to run Studies Within A Trial, or 
SWATs.  These are self-contained research studies embedded within a host trial that aim 
to evaluate or explore alternative ways of delivering or organising a particular trial process.    
 
SWATs are increasingly being supported by funders and considered by trialists, especially 
in the UK and Ireland.  At some point, increasing SWAT evidence will lead funders and 
trialists to ask : given the current body of evidence for a SWAT, do we need a further 
evaluation in a another host trial?  A framework for answering such a question is needed 
to avoid SWATs themselves contributing to research waste.   
 
This paper presents criteria on when enough evidence is available for SWATs that use 
randomised allocation to compare different interventions.     
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Introduction 
The evidence available to inform many routine process decisions in randomised trials is 
thin or weak. This includes the evidence on how best to recruit participants1, retain them2, 
collect their data3 or include them in decisions about the trial4.  While evidence gaps in, 
say, the clinical management of diabetes might be expected to lead to a sustained and 
substantial research effort to fill them, similar effortthis has not happenedmaterialised for 
trial methods research. Recruitment remains a major concern5,6 despite more than 25,000 
new trials opening every year and needing to recruit participants7.  Once recruited, there is 
also little evidence available to inform decisions about how to encourage trial participants 
to remain in the trial and, for example to attend face-to-face measurement visits, which are 
a vital part of most trials2.  Further, there is almost no evidence base to inform trial 
management decisions, including how to select sites, whether visiting them in person is 
worth it, or how to train staff8.   
 
Theis lack of trial process evidence contributes to research waste – for example through 
poor recruitment, retention and data quality – and has been a feature of medical research 
for decades9, with some suggesting that up to 85% of medical research spending is 
wasted10.  However, much of the waste is avoidable11 and research funders recognise the 
need to avoid it12.   
 
Trial Forge (http://www.trialforge.org) is an initiative that aims to improve the efficiency of 
trials, particularly by filling gaps in trial process evidence13.  One way of improving the 
evidence base for trial process decisions is to do a Study Within A Trial (SWAT)14, which is 
a ‘...self-contained research study that has been embedded within a host trial with the aim 
of evaluating or exploring alternative ways of delivering or organising a particular trial 
process’ 15.  For example, a SWAT could evaluate a new way of presenting information to 
potential participants as a way of improving trial retention, perhaps by being clearer about 
what taking part in the trial entails.  Half of potential participants could be randomised to 
receive the new information while the other hand receive the standard information.  The 
effect of the new information on trial retention could be measured at the end of the trial, or 
possibly part-way through if the trial has a long duration.  Other interventions that could be 
evaluated in a SWAT include remote site training compared to face-to-face training, 
sending participants thank-you letters after attending trial visits and sending birthday cards 
to children in paediatric trials to improve retention.  Any improvements that will arise from 
using an alternative approach for a particular process are likely to be modest but the 
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combined effect of small improvements across many processes may well be substantial.  
This is the idea of marginal gains: lots of small gains add up.   
 
There is a growing repository of protocols for SWATs (http://bit.ly/20ZqazA) and 
Madurasinghe and colleagues have developed a reporting standard for recruitment 
SWATs, which are a priority for trial methodology research16-18.  Moreover, major funders 
are taking the need for SWATs seriously as a vehicle for more efficient use of public 
resources.  For example, the UK’s National Institute for Health Research Health 
Technology Assessment program (NIHR HTA) now highlights SWAT funding in all its trial 
funding calls19 and was the topic of a recent ‘HTA Director’s Message’ 
(https://www.youtube.com/watch?v=PoIE6xxK-pA). The Health Research Board Trial 
Methodology Research Network (HRB-TMRN) in Ireland also funds SWATs2019 and the 
Health Research Board encourages investigators to include a SWAT when applying for 
funding for both feasibility and definitive trial funding201.   
 
An important question to ask when thinking about undertaking SWATs is how to prioritise 
interventions for their first evaluation in a SWAT.  A good example of a prioritisation 
process for unanswered questions for trial recruitment is the PRioRiTY project18 
(https://priorityresearch.ie). PRioIORiITY 2 doesis doing the same for trial retention21 
(https://www.trialforge.org/priority-two/).  Future Trial Forge guidance will tackle how to 
combine the results of these prioritisation processes with uncertainties highlighted in 
systematic reviews and elsewhere. 
 
The scope of this guidance documente work described here is what happens after the first 
evaluationfocuses on another important issue.  : Wwhen evidence is available for an 
intervention or some aspect of the trial process, how should one decide if further 
evaluation is needed in another SWAT?  Deciding whether a particular intervention needs 
further evaluation will always be a judgement.  The objective of this Trial Forge guidance is 
provide a framework for making this an informed judgement based on explicit criteria that 
most trialists and methodologists can agree with.  We also take a pragmatic stance about 
evidence generation: trial teams need enough evidence to know whether something is 
worth doing, no more and no less.  The aim is to avoid wasting research effort evaluating 
interventions for which there is already good enough evidence for decision-making, 
allowing attention to re-focus on those interventions where important uncertainty still 
exists.  This paper presents criteria for how to do this for SWATs that use randomised 
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allocation to compare different interventions.  Future Trial Forge guidance may look at the 
same issue for SWATs that use other study designs, or which do not involve interventions.   
 
The guidance is written from the perspective of whether a single research team should do 
a further single evaluation of a SWAT in a single host trial as this is currently the most 
likely approach to doing a SWAT.  An alternative and more efficient approach would be to 
coordinate multiple evaluations of a SWAT in several host trials in parallel, as done in the 
MRC START project22.  One advantage of this approach is speed – production of a body 
of evidence in a shorter time – but also it explicitly sets out to evaluate the SWAT using the 
same protocol, methods and outcomes and, importantly, do those evaluations across 
different host trial contexts.  Coordinated evaluations will, we hope, be done more often in 
the future.  Although we take a single SWAT perspective in this guidance, we expect it to 
apply equally well to SWATs done as part of a coordinated package of evaluations.        
 
Finally, this guidance arose from discussions during and after a meeting in Aberdeen, UK 
on 23 March 2017, as part of the Trial Forge initiative.   
 
 
Proposed criteria for mMaking informed judgements about further 
SWAT evaluation 
Deciding whether a particular intervention needs further evaluation within SWATs will 
always be a judgement based on a variety of information.  What we want to do in this Trial 
Forge guidance is provide a framework for making this an informed judgement based on 
explicit criteria that most trialists and methodologists can agree with.  We also take a 
pragmatic stance about evidence generation: trial teams need enough evidence to know 
whether something is worth doing, no more and no less.  The aim is to avoid wasting 
research effort evaluating interventions for which there is already good enough evidence 
for decision-making, allowing attention to re-focus on those interventions where important 
uncertainty still exists.   
 
The first things to consider are: 
5.1. Whose decision are the SWAT results intended to support? 
6.2. What outcome information do those individuals need to make their decision? 
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The main users of SWAT results will be members of trial teams, since they are the ones 
who decide whether to use the intervention or not in their existing or future trials.  Funders 
of SWATs (and trials) will also be interested.  We need therefore to consider how these 
users would use the accumulating evidence from a series of SWATs on the same topic 
and whether an additional SWAT would make a difference to their decision-making.  
9.3.  
This brings us to outcomes.  What is the ideal bunch of outcomes that a trial team or 
funder would need to make a decision about whether there is enough SWAT evidence for 
decision-making, or whether a further evaluation is needed?  Ideally, the evidence for 
these outcomes should be presented as a cumulative meta-analysis, giving both the most 
up-to-date effect estimate and an indication of whether effect estimates are converging 
with time.  If the estimate is not fluctuating substantially, further evaluations may improve 
precision but this greater precision may not be needed to improve the quality of decision-
making.  We should also like the GRADE certainty of the evidence for each outcome to be 
‘high’ before a decision is taken that a new evaluation might not be needed because a 
high rating provides more confidence in the effect estimate for the outcome.     
 
After considering the overall strength of all the related evidence for a specific outcome, we 
then need to make judgements about its applicability to the context in which a new SWAT 
evaluation is being considered.  This is similar to the thought process for deciding whether 
a new trial is needed of a healthcare intervention that has already been tested in several 
trials.  Indeed, the PICOT framework that is often used for summarising the design of a 
clinical trial can be used to guide decisions about whether the specific elements of a 
proposed SWAT evaluation are sufficiently different to the existing evaluations to warrant a 
further SWAT.      
 
The main users of SWAT results will be members of trial teams. Funders of SWATs and 
trials are also likely to be interested.  To make informed judgements, these users need to 
know what the accumulating evidence is for the effect of the SWAT on one or more 
relevant trial process outcomes (e.g. recruitment, retention), as well as what is the 
certainty in that evidence.  They will want to know whether the evidence comes from 
evaluations done in contexts similar to their own.  Finally, they will want to know how finely 
balanced the advantages and disadvantages of using the SWAT are, both for trial 
participants and the host trial. 
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Given the above, tThe five criteria we propose for deciding whether a further SWAT 
evaluation is needed are listed in Box 1.  The aim of applying these criteria is to ensure 
that the need for a new evaluation is considered explicitly in light of what is already known 
about the intervention. Generally speaking, the more criteria that are met, the more likely 
the conclusion that a new evaluation in a SWAT is appropriate.  Conversely, if none of the 
criteria are met it is unlikely that a new evaluation would be appropriate.        
 
Box 1: Should we do a further evaluation of the intervention in a SWAT?   
The five proposed criteria for deciding whether the intervention needs another evaluation 
in a SWAT.  The more criteria that are met, the more likely we are to conclude that further 
evaluation in a SWAT is appropriate.    
 
1. GRADE: the GRADE22 certainty in the evidence for all key outcomes is lower than 
‘high’.i 
2. Cumulated evidence: the cumulative meta-analysis shows that the effect estimate for 
each outcome essential to make an informed decision has not converged.ii, iii 
3. GRADE: the GRADE certainty in the evidence for all outcomes is lower than ‘high’.iii 
4. Context: the range of host trial contexts evaluated to date does not translate easily to 
the context of the proposed SWATiv.  For the proposed SWAT consider PICOT23: 
• P – is the population in the host trial so different from those already included that 
the current evidence does not provide sufficient certainty? 
• I – are the health interventions in the host trial so different from those already 
included that the current evidence does not provide sufficient certainty? 
• C – is the comparator in the host trial so different from those already included that 
the current evidence does not provide sufficient certainty? 
• O – is the SWAT outcome(s) so different to those used in the existing evaluations 
that that the current evidence does not provide sufficient certainty? 
• T – in the time since the existing evaluations were done, have regulatory, 
technological or societal changes made those evaluations less relevant? 
4. Balance– participants: the balance of benefit and disadvantage to participants in the 
host trial and/or the SWAT is not clearv. 
5. Balance– host trial: the balance of benefit and disadvantage to the new host trial is not 
clear. 
 
Notes 
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i. A GRADE assessment of ‘high’ means that we are confident that the true effect lies close to the 
estimate of effect coming from the cumulative meta-analysis24.  In Cochrane’s deliberations as to when 
to close a Cochrane Review 
(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.ED000107/full), the collaboration chose 
not to require ‘high’ GRADE certainty in the evidence because it was felt that this may not always be 
achievable. Although we recognise the pragmatic nature of this, we recommend ‘high‘ in our criteria 
because SWATs are usually simple studies for which it should be possible to generate high certainty 
evidence. We will, however, keep this criterion under review to consider whether it needs relaxing. A 
GRADE assessment of ‘high’ means that we are confident that the true effect lies close to the estimate 
of effect coming from the cumulative meta-analysis24.  In Cochrane’s deliberations as to when to close a 
Cochrane Review (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.ED000107/full), the 
collaboration chose not to require ‘high’ GRADE certainty in the evidence because it was felt that this 
may not always be achievable. Although we recognise the pragmatic nature of this, we recommend 
‘high‘ in our criteria because SWATs are usually simple studies for which it should be possible to 
generate high certainty evidence. We will, however, keep this criterion under review to consider whether 
it needs relaxing. 
ii. This is a judgement that depends on the behaviour of the effect estimates and on whether the 
confidence intervals include the threshold for an important benefit (or disadvantage).  For example, if 
there is drift in the effect estimates of a meta-analyses but the confidence intervals around the 
estimates are consistently above what you think is an important benefit (or below a relevant 
disadvantage) then the cumulative meta-analysis can be judged to have converged despite movement 
in the effect estimates.  For more on GRADE see http://www.gradeworkinggroup.org.  
iii. A cumulative meta-analysis requires the same outcomes to have been measured in the same way in 
the studies to be combined.  Most SWAT protocols specify just one or perhaps two outcomes, which 
reduces the scope for different outcomes between evaluations.  Tighter specification of outcomes on 
SWAT protocols would help even more (e.g. retention sounds simple but could mean the proportion of 
participants who remain in the trial, the proportion who return a form, or the proportion who fully 
complete all forms).  Core outcome sets for trial processes may help and this is being done in ELICIT 
for interventions to improve informed consent243. 
This is a judgement that depends on the behaviour of the effect estimates and on whether the confidence 
intervals include the threshold for an important benefit (or disadvantage).  For example, if there is drift in the 
effect estimates of a meta-analyses but the confidence intervals around the estimates are consistently above 
what you think is an important benefit (or below a relevant disadvantage) then the cumulative meta-analysis 
can be judged to have converged despite movement in the effect estimates.   
A GRADE assessment of ‘high’ means that we are confident that the true effect lies close to the estimate of 
effect coming from the cumulative meta-analysis24.  In Cochrane’s deliberations as to when to close a 
Cochrane Review (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.ED000107/full), the 
collaboration chose not to require ‘high’ GRADE certainty in the evidence because it was felt that this may 
not always be achievable. Although we recognise the pragmatic nature of this, we recommend ‘high‘ in our 
criteria because SWATs are usually simple studies for which it should be possible to generate high certainty 
evidence. We will, however, keep this criterion under review to consider whether it needs relaxing.   
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iv. This is to provide reassurance about the applicability of the result to different types of trials.  Care is 
needed to avoid a default position of insisting on an evaluation in every conceivable context.  In other 
words, is there any reason to believe that the intervention would not work in your context given the 
contexts already studied?  It is possible that evidence from SWATs will eventually splinter off to focus 
specifically on certain contexts but, for now, we suggest pooling evaluations of the same intervention 
because there are so few SWAT evaluations of any intervention and this pooling will provide a basic 
foundation on which to build.   
v. Where there may be no conceivable benefit or disadvantage for participants, they should be considered 
as balanced. 
 
To illustrate the use of these criteria, we have applied them to examples from the 
Cochrane Review on strategies to improve trial recruitment1 and the Cochrane Review on 
strategies to improve trial retention2.  
 
Example 1: Telephoning non-responders to trial invitations 
Background 
Only two interventions in the 2018 version of the Cochrane Review for trial recruitment1 
have both high certainty for the evidence and a potential for widespread applicability.  One 
of these is telephoning people who do not respond to postal invitations to take part in a 
trial, which is used in this example. (The other relates to optimising the patient information 
leaflet.)  The Cochrane Review notes that the rating of high certainty is only for trials with 
low underlying recruitment of less than 10% of eligible participants.  If the evidence is to be 
applied to trials with higher underlying recruitment, the review authors suggested that the 
GRADE rating be reduced from high to moderate because of indirectness.   
 
 
A trial team that includes people with lived experience of the illness or condition targeted is 
likely to consider information about the following essential when deciding whether a further 
evaluation of telephone reminders should form part of their recruitment strategy:   
i) effect on recruitment 
ii) cost 
iii) participant irritation at receiving the telephone call 
 
Applying the five criteria 
Table 1 summarises the results of the two telephone reminder trials and the overall 
estimate of effect.        
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The meta-analysis of the results of these two trials suggests that telephoning non-
respondents increases recruitment by between 3% and 9%, with a best estimate of the 
increase being 6%.  The Cochrane Review also notes that the two trials both have low 
underlying recruitment of less than 10% of eligible participants.  Therefore, if the evidence 
is to be applied to trials with higher underlying recruitment, the review authors suggested 
that the GRADE rating be reduced from high to moderate because of indirectness.  
 
A trial team making a decision about whether to use telephone reminders is likely to 
consider the following outcomes essential for that decision:   
recruitment 
cost 
participant irritation at receiving the call 
 
Applying the criteria in Box 1: 
 
1. GRADE.  Data are available for recruitment only.  The GRADE certainty in the 
evidence is high for the two included trials but is moderate for trials that do not have 
low (<10%) underlying recruitment. Criterion partially met (the GRADE certainty in 
the evidence for all essential outcomes is lower than ‘high’).  
2. Cumulative evidence.  Data are available for recruitment only.  There are only two 
trials and it seems too early to claim the cumulative meta-analysis has converged.  
Criterion met (the effect estimate for each essential outcome has not converged). 
3. GRADE.  The GRADE certainty in the evidence is high for the two included trials 
but is moderate for trials that do not have low (<10%) underlying recruitment. 
Criterion partially met (the GRADE certainty in the evidence for all essential 
outcomes is lower than ‘high’). 
4. Context.  The PICOT for the available evidence is: 
• P – One study was done in Norway in 2002/3 and involved people aged 16 to 66 
who were sick-listed for more than seven weeks due to non-severe 
psychological problems or musculoskeletal pain.  The second study was done in 
Canada in 2010 and involved people aged 50 to 70 years from family practice 
lists who were eligible for colorectal cancer screening.  
• I – The host trial intervention in the Norwegian study was solution-focused 
sessions led by psychologists that were one-on-one or in groups and aimed to 
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help people get back to work.  The host trial interventions in the Canadian study 
were one of virtual colonoscopy, optical colonoscopy or fecal occult blood 
testing.   
• C - The host trial comparator in the Norwegian study was usual care: written 
information from the social security office.  The Canadian host trial was doing a 
head-to-head evaluation of three screening methods so the three interventions 
mentioned above were also the comparators. 
• O – Both studies measured recruitment to the host trial.  Both host trials had low 
underlying recruitment. 
• T – Mobile telephones have replaced home-based phones for many people and 
neither study explicitly includes mobile telephones. 
One study was done in Norway and looked at recruitment to a trial testing an 
intervention to help people get back to work after illness; calls were made by the 
research team.  The other study was done in Canada and looked at recruitment to a 
colorectal cancer screening trial; calls were made by research nurses.  Both had 
low underlying recruitment.  Since these studies were done, mobile telephones 
have replaced home-based telephones for many people and neither study explicitly 
includes mobile telephonesConsidering the above, leads to .  Criterion partially 
met (a new evaluation is likely to contain several elements in the PICOT that are 
importantly different to those in the two existing evaluations). 
5. Balance– participants.  There is little or no direct benefit to participants, although 
some may like being reminded about the trial.  One potential disadvantage is that 
some participants may be irritated by the reminder call but what proportion would be 
irritated is unclear.  Criterion met (the balance of benefit and disadvantage to 
participants in the new host trial and/or SWAT is not clear) 
6. Balance– host trial.  The benefit to the host trial is a small increase in recruitment if 
underlying recruitment is low but it is unclear what the benefit would be if underlying 
recruitment was higher.  There is a potential disadvantage to the host trial of over-
burdening trial staff with making the reminder telephone calls but the size of this 
disadvantage is unclear.  Criterion met (the balance of benefit and disadvantage to 
those running the host trial is not clear) 
 
Considering the responses across all five criteria leads us to conclude that So, would 
anotherfurther evaluation of telephone reminders be worth doing?is needed  Yes, based 
on the above, and especially where underlying recruitment is anticipated to be higher than 
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10%.  More information on The views of people with lived experience of the conditions 
targeted by host trials on receiving telephone reminder calls should be sought in future 
evaluations. More information on cost and the potential disadvantages for the both 
participants and host trial would also be welcome, as would evaluations that used mobile 
telephones.   
 
Figure 1 shows how the evidence with regard to telephone reminders for recruitment might 
be shown on the Trial Forge website.  The cumulative meta-analysis in this summary 
shows four decision thresholds (absolute difference of 0%, 5%, 10% and 15%) that trialists 
can use when deciding whether they want to use the intervention in their own trial based 
on the current evidence.  A trialist looking for a 10% or better increase in recruitment would 
probably decide that telephone reminders are not worth the effort, especially if underlying 
recruitment is not expected to be low.  While a trialist expecting very low underlying 
recruitment might decide that any increase, even a small one, is worth having and plan 
their resource use accordingly.  In both circumstances, the trialists would need to 
speculate on the balance of benefit to disadvantage.     
 
Example 2: monetary incentives to increase response rates to trial 
questionnaires 
Background 
The 2013 Cochrane Review of interventions to improve trial retention2 found that monetary 
incentives seem to improve response rates to trial questionnaires.   
A trial team that includes people with lived experience of the illness or condition targeted is 
likely to consider information about the following essential when deciding whether a further 
evaluation of financial incentives should form part of their retention strategy:   
i) effect on questionnaire response rate (retention) 
ii) cost 
iii) participant irritation at receiving a small, unsolicited gift 
 
Applying the five criteria 
Table 2 summarises the results of the three monetary incentives trials and the overall 
estimate of effect.  
 
A trial team making a decision about whether to use financial incentives is likely to 
consider the following outcomes essential for that decision:   
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questionnaire response rate (retention) 
cost 
participant irritation at receiving a small, unsolicited gift 
 
Applying the criteria in Box 1: 
 
1. GRADE.  Data are available for questionnaire response rates only. The overall 
GRADE certainty in the evidence is moderate.  Criterion met (the GRADE certainty 
in the evidence for all essential outcomes is lower than ‘high’).  
2. Cumulative evidence.  Data are available for questionnaire response rates only.  
There are only three trials and it seems too early to claim that the cumulative meta-
analysis has converged.  Criterion met (the effect estimate for each essential 
outcome has not converged). 
GRADE.  The overall GRADE certainty in the evidence is moderate.  Criterion met (the 
GRADE certainty in the evidence for all essential outcomes is lower than ‘high’). 
3. Context.  The PICOT for the available evidence is:  
• P – Two trials were done in the UK, one in 2002/3 and the other in 2007/8.  The 
first involved women who had had a baby, and their partners.  The second UK 
study involved people over the age of 18 who attended emergency departments 
with a whiplash injury of less than six weeks duration.  A third trial was done in 
the US in 2001 and involved smokers who wanted to stop.     
• I – The host trial intervention in the 2002/3 UK study was an antibiotic, while in 
the 2007/8 UK study the host trial intervention was a book of advice about 
whiplash, with that advice being reinforced depending on the persistence of 
symptoms. The host trial intervention in the US study was a community-based 
program of public education, advice from health care providers, work-site 
initiatives and smoking cessation resources.   
• C - The host trial comparator in the 2002/3 UK study was placebo and usual 
whiplash advice in the 2007/8 UK study.  The host trial comparator in the 2001 
study was no community-based smoking cessation program.  
• O – All studies measured retention to the host trial.  All three host trials had 
underlying retention below 50%. 
• T – The most recent of these studies was done in 2007/8 so inflation and other 
societal changes may affect the attractiveness of the amounts paid. 
Two trials were done in the UK and the third was from the USA.  The two UK 
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studies used shopping vouchers and the USA study used cheques.  One host trial 
looked at smoking cessation (USA), one at improving neonatal outcomes, and the 
other at improving neck injury outcomes.  The incentive was compared to no 
incentive in the three studies. The two UK studies sent the incentive together with a 
trial questionnaire; the USA study sent the incentive together with the request to 
send a DNA sample.  All three host trials had underlying retention below 50%.  The 
most recent of these studies was done in 2009 so inflation and other societal 
changes may affect the attractiveness of the amounts paid.  Considering the above, 
leads to Criterion partially met  (a new evaluation is likely to contain several 
elements in the PICOT that are importantly different to those in the three existing 
evaluations). 
4. Balance– participants.  There is modest financial benefit to participants who receive 
the incentive. The potential disadvantage of a participant feeling coerced to provide 
questionnaire data seems low given the size of financial incentive being offered in 
these trials (US$10 or less) although whether these small amounts are perceived as 
insulting or irritating is unclear.  Criterion partially met (the balance of benefit and 
disadvantage to participants in the new host trial and/or SWAT is not clear). 
5. Balance– host trial. The benefit to the host trial is a modest increase in response 
rates.  The potential disadvantage to the host trial of the costs of providing the 
incentives is quantifiable.  Workload may be increased (e.g. someone has to 
manage vouchers or other incentives) but this is unlikely to be much larger than the 
work needed anyway to send out questionnaires. Criterion not met (the balance of 
benefit and disadvantage to those running the host trial is clear and can be 
estimated for each trial depending on the size of the incentive). 
 
So, would another evaluation of incentives be worthwhile?Considering the responses 
across all five criteria leads us to conclude that further evaluation of financial incentives is 
needed  Yes, based on the above and with priority given to evaluation in trials expected to 
have underlying retention above 50%.  The views of people with lived experience of the 
conditions targeted by host trials on receiving small, unsolicited payments should be 
sought in future evaluations.  FThese future randomised evaluations should ensure that 
they are assessed as at low risk of bias on the Cochrane Risk of Bias tool25 to move the 
GRADE assessment from moderate to high.  More information on the views of participants 
about receiving small, unsolicited payments would be welcome.     
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Figure 2 shows how Trial Forge might summarise the evidence with regard to monetary 
incentives for retention. 
 
Discussion 
Trial Forge is an initiative to strengthen the evidence base for trial process decision-
making, as one step towards improving the effectiveness and efficiency of those 
processes. SWATs are an important way of contributing to that evidence base.  However, 
in order to minimise research waste arising from the SWATs themselves, their designers 
need to be confident that enough evidence is not already available from evaluations of a 
given intervention to support good, evidence-informed decisions.    
 
The five criteria shown in Box 1 provide a basis to determine whether this is the casethis.  
Although this approach requires judgement, it provides a transparent mechanism for 
deciding whether the cumulative meta-analysis, GRADE assessment of the certainty of the 
existing evidence, cumulative meta-analysis, host trial contexts and balance of benefit and 
disadvantage suggest that there is merit in evaluating the intervention in more SWATs, or 
whether there is already enough information to support evidence-informed decision-
making about the relevant trial process.  It also provides a way to frame and track 
discussion between researchers on particular SWATs – recognising that there will be 
disagreements but providing clarity about these disagreements and subsequent decision-
making.  Moreover, using this approach will help to identify and prioritise SWATs where 
there is existing but insufficient evidence and the type of host trials that should to be 
targeted to build the evidence base.  The criteria can also be used with decision 
thresholds (e.g. benefits of 5%, 10%, 15% or more) to help people decide whether they 
want to use the intervention based on the existing evidence even if more evaluations are 
needed.  
 
We will pilot this technique and the five criteria for those SWATs promoted through Trial 
Forge, making clear statements for these evaluations akin to those given above for the two  
examples.  We expect that the technique will be refined and improved over time but, for 
now, the approach provides a starting foundation.  Some areas that need work are 
mentioned below as limitations.  The criteria might also be linked to the SWAT repository 
(http://bit.ly/20ZqazA), to improve the accessibility of SWAT results and ongoing SWAT 
evaluations.  Showing that the criteria support a further evaluation of an intervention in a 
SWAT is also likely to be helpful to those deciding about applications for funding of new 
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SWAT evaluations by providing reassurance about the need for the work and its 
contribution to the body of evidence.  
 
There are some limitations.  The sparseness of the trial process evidence base means that 
it is currently unlikely that applying the five criteria to any body of evidence will lead to a 
decision not to start another evaluation.  We did want to include an example that would 
have shown the criteria concluding that more evaluations were not needed but we could 
not find one. In addition, the criteria have been developed by a group of SWAT enthusiasts 
who are based mainly in the UK or Ireland. Others may prefer different criteria and we 
hope that this paper will stimulate discussion and lead to refinements as these and other 
criteria are applied.  Another limitation is the potential for publication bias.  Anecdotally, we 
know that some SWATs are done but not published, which means our evidence 
summaries and judgements could suffer from publication bias.  As others have noted26, it 
is extremely difficult to be certain that publication bias is absent but by including GRADE, 
our criteria do include an explicit consideration of the potential for  publication bias.   
Applying our criteria systematically across many SWAT interventions will also need 
resources. Finding these might be a challenge but our hope is that by demonstrating the 
value of the criteria in reducing research waste by highlighting when further evaluations of 
a SWAT are (or are not) needed will make it easier to secure resources in the future.   
 
The most troubling limitation is likely to relate to the third criterion and the issue of context, 
which is no less thorny in SWATs than it is in the host trials in which they sit.  We suggest 
a PICOT framework to consider contextual factors and there may be a need for additional 
factors to be considered.  For example our criteria do not explicitly dwell on the 
behavioural theory or mechanism of action behind a SWAT intervention and whether 
theseis theories and mechanisms still applyies outside the context in which the 
intervention was developed.  Our criteriaThis may need to change, especially as bodies of 
SWAT evidence get larger.  We welcome suggestions for the key variables needed by trial 
teams and others to make judgements about context, which can then be considered for 
inclusion in the Context criterion. 
 
Finally, in a spirt of pragmatism about evidence generation, we recognise that less than 
perfect might be good enough and certainly better than no evidence at all. This may mean 
that the most efficient way of approaching the limited time and money available for 
evidence generation about trial processes may be to focus on whether something clears a 
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threshold that makes it worth doing, rather than having a precise estimate of its effect. This 
suggests that tThere would be little to gain from pursuing perfection if it will not change 
decisions. and that, iIf we want to avoid wasting resources and participant goodwill, we 
need to think carefully about when enough is enough.  
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